Zacks Investment ResearchSep 1, 12:02 PM ET▲ Positive
Company's PD-1 inhibitor Tevimbra demonstrated improved OS hazard ratios when combined with Ziihera and chemotherapy in the three-drug regimen, supporting its clinical value in this indication.
BeOne Medicines news
$365.27−0.47%
Close Sep 29, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive1100% of coverage
Neutral00%
Negative00% of coverage
About BeOne Medicines
No recent articles focused on BeOne Medicines.
Also mentions ONC
Articles that tag ONC but are mainly about other companies.
GlobeNewswire Inc.May 13, 6:00 AM ETNeutral
BeOne Medicines is mentioned only as a partner with exclusive development and commercialization rights for zanidatamab in different territories. No specific updates or developments regarding this company are provided.
GlobeNewswire Inc.Mar 23, 9:00 AM ETNeutral
Mentioned only as the current employer of the incoming board member; no direct business impact or news related to BeOne Medicines itself.
GlobeNewswire Inc.Feb 12, 6:00 AM ETNeutral
BeOne Medicines is mentioned only as a partner with exclusive commercialization rights for zanidatamab in certain territories. No specific information about their performance or involvement is provided.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology